Saturday 17 October 2026
Export BVS’s income statement to Excel — free account
Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
13.30
0.51
−3.69%
Follow BVS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
55.75 | 21.88 | 21.23 | 11.65 |
P/S ratio |
0.79 | 0.87 | 1.07 | 1.10 | |
P/FCF ratio |
8.37 | 6.87 | 6.11 | 6.80 | |
P/Operating CF |
14.88 | 13.06 | 68.77 | 32.24 | |
P/B ratio |
2.16 | 2.17 | 2.62 | 2.31 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.29 | 1.30 | 1.48 | 1.48 | |
EV/EBITDA |
8.10 | 7.31 | 8.19 | 8.30 | |
EV/Operating CF |
13.00 | 9.89 | 8.26 | 8.87 | |
EV/FCF |
13.62 | 10.24 | 8.45 | 9.12 | |
Quick Ratio |
1.07 | 1.12 | 1.06 | 1.10 | |
Current Ratio |
1.74 | 1.70 | 1.69 | 1.69 | |
Net Debt/EBITDA |
12.38 | 7.78 | 12.04 | 7.28 | |
Debt/Assets |
45.98% | 43.00% | 41.82% | 36.90% | |
Debt/Equity |
1.56 | 1.29 | 1.16 | 0.90 | |
Asset Turnover |
0.77 | 0.80 | 0.86 | 0.84 | |
Operating CF/Net income |
9.54 | 2.57 | 2.87 | 0.59 | |
Capex/Depreciation |
(0.04) | (0.05) | (0.05) | (0.09) | |
Interest Coverage |
1.82 | 3.67 | 1.95 | 4.70 | |
Research and Development Expense of Revenue |
2.11% | 1.90% | 1.87% | 2.07% | |
Selling, General and Administrative Expense of Revenue |
56.73% | 52.41% | 59.30% | 54.01% | |
Intangible Assets out of Total Assets |
0.55 | 0.55 | 0.56 | 0.53 | |
Share Based Compensation of Revenue |
2.29% | 2.18% | 2.47% | 3.29% | |
Graham Net Nets |
(0.48) | (0.37) | (0.27) | (0.22) | |
Graham Number |
2.89 | 5.12 | 5.80 | 8.63 | |
Earnings Yield |
1.79% | 4.57% | 4.71% | 8.58% | |
Free Cash Flow Yield |
11.94% | 14.55% | 16.38% | 14.72% | |
Revenue per Share |
2.07 | 2.37 | 1.96 | 2.26 | |
Operating CF per Share |
0.45 | 0.57 | 0.13 | 0.29 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.44 | 0.56 | 0.12 | 0.28 | |
Cash per Share |
0.63 | 0.77 | 0.53 | 0.43 | |
Shareholders Equity per Share |
3.10 | 3.43 | 3.48 | 4.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.10 | 3.43 | 3.48 | 4.09 | |
Free Cash Flow |
29.63 | 37.39 | 8.36 | 18.91 | |
Working Capital |
119.15 | 112.46 | 101.72 | 105.08 | |
Capital Expenditures |
(0.47) | (0.58) | (0.57) | (0.96) | |
Net Current Asset Value |
(213.44) | (182.27) | (166.46) | (138.41) | |
EV/EBIT |
17.26 | 13.68 | 14.79 | 14.75 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
10.61 | 9.18 | 10.68 | 10.99 | |
| Other line items | |||||
Average Receivables |
126.16 | 127.85 | 119.30 | 135.39 | |
Average Payables |
21.75 | 17.31 | 21.62 | 22.22 | |
Average Inventory |
93.15 | 87.36 | 88.62 | 88.14 | |
Average Assets |
735.54 | 705.76 | 670.98 | 690.07 | |
Average Common Equity |
197.04 | 207.03 | 209.87 | 239.36 |
Columns are period end dates